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Strengths and limitations of this study
 ► This study could provide valuable information on the 
possibility of unascertained prion disease occurring 
in the over 65-year age group.
 ► The study includes five biochemical analysis meth-
ods, which are used in research for the detection 
of the abnormal misfolded prion protein associated 
with prion diseases.
 ► Two of these biochemical methods (western blot-
ting and real-time quaking-induced conversion) are 
routinely used in the diagnosis of prion disease at 
National Creutzfeldt-Jakob Disease Research & 
Surveillance Unit.
 ► The other three methods have been used in re-
search, but have not been used routinely as tools for 
prion disease diagnosis or surveillance.
 ► This study is restricted to the Scottish population, 
but the approaches used may be applicable to UK-
wide enhanced CJD surveillance in the 65+ years 
population group, in the future.
AbStrACt
Introduction Creutzfeldt-Jakob disease (CJD) is a 
human prion disease that occurs in sporadic, genetic and 
acquired forms. Variant CJD (vCJD) is an acquired form 
first identified in 1996 in the UK. To date, 178 cases of 
vCJD have been reported in the UK, most of which have 
been associated with dietary exposure to the bovine 
spongiform encephalopathy agent. Most vCJD cases have 
a young age of onset, with a median age at death of 28 
years. In the UK, suspected cases of vCJD are reported 
to the UK National Creutzfeldt-Jakob Disease Research 
& Surveillance Unit (NCJDRSU). There is, however, a 
concern that the national surveillance system might be 
missing some cases of vCJD or other forms of human 
prion disease, particularly in the older population, perhaps 
because of atypical clinical presentation. This study aims 
to establish whether there is unrecognised prion disease in 
people aged 65 years and above in the Scottish population 
by screening banked brain tissue donated to the Edinburgh 
Brain Bank (EBB).
Methods Neuropathological screening of prospective 
and retrospective brain tissue samples is performed. This 
involves histopathological and immunohistochemical 
analysis and prion protein biochemical analysis. During 
the study, descriptive statistics are used to describe the 
study population, including the demographics and clinical, 
pathological and referral characteristics. Controlling for 
confounders, univariate and multivariate analyses will be 
used to compare select characteristics of newly identified 
suspect cases with previously confirmed cases referred to 
the NCJDRSU.
Ethics and dissemination Brain tissue donations to 
EBB are made voluntarily by the relatives of patients, with 
consent for use in research. The EBB has ethical approval 
to provide tissue samples to research projects (REC 
reference 16/ES/0084). The findings of this study will be 
disseminated in meetings, conferences, workshops and as 
peer-reviewed publications.
trial registration numbers 10/S1402/69 and 10/
S1402/70
IntroduCtIon
Human prion diseases are rare, invariably 
fatal neurodegenerative diseases associated 
with an abnormal misfolded form of the 
prion protein (PrP), designated as PrPSc. 
The most common human prion disease is 
Creutzfeldt-Jakob disease (CJD), which is 
mainly idiopathic in origin, occurring sporad-
ically worldwide at a rate of one to two cases 
per million population per year. A variant 
form (vCJD) is associated with dietary expo-
sure to bovine spongiform encephalopathy, 
although person-to-person transmission of 
vCJD infection has also occurred through 
both blood and possibly blood products.1 2 In 
contrast to the sporadic form (sporadic CJD, 
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Table 1 Sources of donations to EBB
Source Description
65+ study Includes donations from participants who are 65 years and older across Edinburgh and NHS 
Lothian, including the Anne Rowling Clinic, Old Age Psychiatry, Medicine of the Elderly and 
Neurology services, with atypical features of dementia
Alzheimer Scotland Includes donations from adults diagnosed with dementia in Scotland
Edinburgh Procurator Fiscal Includes donations from sudden or accidental death investigated by procurator fiscal in 
Scotland
Lothian Birth Cohort 1936 Includes donations from participants born in 1936 in Lothian
Motor Neurone Disease 
Register
Includes donations from patients with motor neurone disease in Scotland
LINCHPIN—Lothian 
IntraCerebral Haemorrhage, 
Pathology, Imaging and 
Neurological Outcome
Includes donations from adults in Lothian diagnosed with intracerebral haemorrhage after 01 
June 2010
Multiple Sclerosis Society 
Tissue Bank
Includes donations from patients with multiple sclerosis in Scotland
EBB, Edinburgh Brain Bank; NHS, National Health Service.
or sCJD) which affects individuals mainly in the seventh 
decade of life, the median age at onset for vCJD in the 
UK is 26.5 years and the median age at death is 28 years.3 
To date, 178 cases of vCJD have been reported in the UK 
with the first cases reported in 1996 and the most recent 
death occurring in 2016.4 However, prevalence studies 
indicate that 1 in 2000 people in the UK may be subclin-
ical carriers of vCJD infection.5–7 Therefore, it is possible 
that future cases of vCJD may occur.4 5 8 9
The national surveillance system for CJD in the UK has 
comprehensive mechanisms in place for the ascertain-
ment of prion disease.3 However, it is possible that the 
national surveillance system could be missing some vCJD 
cases, particularly in older age groups, perhaps because 
the clinical presentation in these individuals is atypical of 
vCJD. For example, age-related changes in the brain may 
mask the MRI signal and characteristic pathology that 
supports the diagnosis of vCJD.10 There is also the poten-
tial that typical cases of vCJD may simply not be recognised 
as such in older individuals, because vCJD patients are 
typically much younger. Furthermore, dementia is also 
relatively common among people aged 65 years and 
above11 and a diagnosis of vCJD may be more difficult to 
recognise, or may not be considered, if the patient has 
been referred to non-neurology medical specialities that 
are less familiar with prion disease. A similar situation 
may also exist for sCJD, which in the UK currently occurs 
at a rate of five to six cases per million of the popula-
tion aged 65 years and above, with mortality peaking in 
the 65–79 years age group and then rapidly declining.3 
The reasons for this rapid decline are unclear, but may, 
in part, be linked to under-ascertainment of cases in the 
elderly, rather than the absence of disease.3
To enable robust and accurate clinical and epide-
miological surveillance of CJD and to help to protect 
public health from the potential iatrogenic transmission 
of CJD,12 the identification and investigation of CJD 
cases across all age groups is essential. This study aims 
to screen banked brain tissue donations for evidence of 
otherwise unrecognised prion disease (including vCJD 
and sCJD) in the 65+ years age group. Specifically the 
study aims:
1. To undertake in-depth histopathological, immunohis-
tochemical, PrP biochemical and molecular subtype 
(PRNP codon 129) screening.
2. To describe the range of clinical and pathological 
characteristics associated with prionopathy, in life (al-
ternative) diagnoses and referral characteristics of any 
‘missed’ cases identified in this screen.
Methods
Study design and population
This study aims to determine if there is otherwise unrec-
ognised prion disease (including vCJD, sCJD and other 
forms of prionopathy) in the Scottish population. The 
approach taken for this part of the study involves neuro-
pathological screening of prospective and retrospective 
brain tissue donations donated to the Edinburgh Brain 
Bank (EBB) from donors in the 65+ years age group 
throughout Scotland.13 14 The testing methods applied 
include histopathological, immunohistochemical and 
PrP biochemical analysis, and genotyping polymorphic 
codon 129 of the PrP gene (PRNP).
Case inclusion definition
All brain tissue donations to the EBB from people aged 
65 years and above are eligible for inclusion in the study. 
Donated tissue is excluded only if there is insufficient 
quantity for planned laboratory investigations. The 
number of eligible donations received at EBB is currently 
estimated at 30 each year. In addition, there are approx-
imately 175 donations already banked at EBB from 2005 
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Figure 1 An overview of processes put in place including neuropathological screening. CJD, Creutzfeldt-Jakob disease; GP, 
general practitioner.
(referred to as retrospective samples), which are eligible 
for screening in this study.
Outcome
Our primary outcome of interest is evidence of prion 
pathology, which includes the presence of abnormal PrP, 
PrPSc, in brain tissue following brain tissue testing. We 
are interested in the associated clinical, pathological and 
referral characteristics, and in life (alternative) diagnosis 
of any cases detected in this way.
Source of samples
The EBB is part of the UK population-wide Brain Bank 
Network, providing high-quality post-mortem materials 
for diagnosis and research into disorders of the brain and 
nervous system. EBB was established in 2005, and receives 
donations from a number of national and local research 
studies in Scotland.13 14 Currently, this includes donations 
made through the National Creutzfeldt-Jakob Disease 
Research & Surveillance Unit (NCJDRSU) 65+ enhanced 
clinical surveillance study, Alzheimer Scotland,15 
Edinburgh Procurator Fiscal, Lothian Birth Cohort 
1936, the Scottish Motor Neurone Disease Register,16 the 
Lothian study of IntraCerebral Haemorrhage, Pathology, 
Imaging and Neurological Outcome,17 and the Multiple 
Sclerosis Society Tissue Bank (table 1). These form a 
highly select patient group with a set of neurodegen-
erative (non-CJD) conditions among which a ‘missed’ 
diagnosis of prionopathy might be found. An overview 
of the protocol put in place including neuropathological 
screening of brain tissue donations is shown in figure 1.
donations to Ebb
All donations made to the EBB are handled by a team 
comprising a neuropathologist(s), research nurse, labo-
ratory technicians and a laboratory manager.18 Neuropa-
thologists provide cellular and molecular diagnoses from 
post-mortem examinations. The research nurse is respon-
sible for obtaining authorisation for a post-mortem exam-
ination and the use of brain tissue for research purposes 
from the families of donors. The research nurse liaises 
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with donor families and funeral directors throughout the 
whole process. The laboratory technicians are responsible 
for collecting and storing the tissue samples and checking 
their quality. The laboratory manager ensures the smooth 
running of the laboratory, including appropriate gover-
nance on tissue sample requests from researchers in the 
UK and internationally.
Sample identification and preparation at Ebb
Once a tissue donation is made to the EBB, staff check its 
eligibility for inclusion into our study. Eligible donations 
are flagged, and the study team at NCJDRSU is informed. 
For all donations made, there is a standard protocol for 
tissue sampling that is applied during the post-mortem 
examination.19 First, the brain is removed and cut into 
coronal slices. These individual brain slices are further 
subsampled to provide a small tissue block from a wide 
range of specified brain regions. Each block of tissue is 
divided into two, with one sample immersed in formalin 
fixative and processed into a paraffin-embedded (FFPE) 
tissue block, and the second sample frozen in liquid 
nitrogen vapour and stored at −80°C. Both frozen and 
fixed samples are stored within the EBB and made acces-
sible for further neuropathological and biochemical 
investigations. From the FFPE tissue blocks, 5 µm thin 
tissue sections are cut and mounted onto glass slides 
(referred to as fixed tissue), and analysed by microscopy 
following H&E staining or immunohistochemical probing 
with specific antibodies. The frozen tissue is subjected to 
biochemical and genotypic analyses. For our study, EBB 
provides both fixed and frozen tissue samples from each 
of the four cortical regions (frontal, temporal, occipital 
and parietal) as well as the thalamus and cerebellum, if 
available.
Sample transportation
The frozen and fixed tissue samples are anonymised 
before being transported to NCJDRSU, and accompa-
nied in transit by a study tissue form containing a unique 
EBB donation identifier number. For the fixed tissue, 
no specific precautions are necessary for transportation. 
However, these samples are packaged appropriately in 
microscope slide boxes to prevent damage in transit. 
Frozen tissue is packaged together with dry ice in accor-
dance with the regulations for road transport of category 
B (UN3373) tissue specimens. Both frozen and fixed 
samples are delivered to NCJDRSU in person by the EBB 
laboratory manager.
Processing of samples at nCJdrSu
Due to the infectious nature of prion diseases, all 
personnel handling frozen tissue samples within the 
NCJDRSU laboratory are required to do so in accor-
dance with NCJDRSU category 3 laboratory health and 
safety policies and national regulations.20 21 Both frozen 
and fixed samples are delivered to the NCJDRSU cate-
gory 3 containment laboratory,20 where they are regis-
tered electronically and tracked within the unit using 
the same unique EBB donation identifier number as in 
section Sample transportation. The frozen samples are 
stored immediately in a designated −80°C freezer, while 
the fixed samples are stored at room temperature in the 
laboratory.
Histopathology testing
For all prospective and retrospective samples, laboratory 
technicians at EBB conduct a standard suite of histo-
pathological screening on the fixed tissue from all the 
six brain regions mentioned in section Sample identifi-
cation and preparation at EBB for the identification of 
pathological changes associated with common neurode-
generative diseases, including screening for spongiform 
change, astrogliosis, neuronal loss and plaque formation. 
This standard suite includes basic immunohistochemical 
analysis using a panel of antibodies against neurodegen-
erative proteins: anti-Aβ40, anti-Aβ42, anti-α-synuclein, 
anti-phospho-tau, anti-phospho-TDP-43 (transactive-re-
sponse DNA-binding protein 43) and anti-p62.
Immunohistochemical testing for PrP
Additional immunohistochemically testing for the PrP in 
the fixed tissues are performed at NCJDRSU using two 
anti-PrP monoclonal antibodies: 12F10, which recognises 
the PrP epitope 142–160 (Bioquote, York, UK), and KG9, 
which recognises the PrP epitope 140–160 (TSE Resource 
Centre, Roslin Institute, Edinburgh, UK). Both are 
used in combination with the highly sensitive Novolink 
Polymer Detection System.22 PrP immunohistochemistry 
is routinely carried out on fixed tissue sections on just 
two of the six brain regions, namely frontal cortex and 
cerebellum. Subsequent analysis on the thalamus and 
the remaining three cortical regions (temporal, occip-
ital and parietal) is conducted if the cases are flagged to 
be of interest following their histopathological and/or 
biochemistry investigations for prion disease.
PrP biochemical analysis
For all prospective samples, this investigation requires 
approximately 2–3 gm of frozen tissue each from the 
frontal, temporal, occipital and parietal cortical regions 
as well as the thalamus and cerebellum, whereas for retro-
spective samples, only the frontal cortex and cerebellum 
are analysed. We use a panel of biochemical analysis 
methods (table 2), which are designed to maximise the 
potential for detecting low levels of prion disease PrPSc. 
These include:
1. Standard diagnostic western blot (WB) for the prote-
ase-resistant core of PrPSc (PrPres)22 23 with samples pre-
pared according to the method of Parchi et al.24
2. High sensitivity sodium phosphotungstic acid precipi-
tation (NaPTA), followed by WB for PrPres.2 25 26
3. Conformation-dependent immunoassay (CDI) analy-
sis for PrPSc.27 This method is highly sensitive and is 
able to detect both protease-resistant and protease-sen-
sitive forms of PrPSc.28 29
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Table 2 Biochemical analysis methods
Method Function of test Advantages Disadvantages References
1. Western blot (WB) Detection of protease-resistant PrPSc Standard method used 
in the diagnosis of 
prion diseases
Relatively low 
analytical sensitivity
22–24
2. Sodium 
phosphotungstic acid 
(NaPTA) precipitation/
western blotting
Concentration and detection of 
protease-resistant PrPSc
Can detect low levels 
of PrPSc, for example, 
in vCJD spleen and 
sCJD muscle
Not tested for use in 
routine diagnostics 
or screening
2 25 26
3. Conformation-
dependent 
immunoassay (CDI)
Detection of PrPSc based on 
concealed epitopes that are 
exposed when PrPSc is denatured
Can detect protease-
sensitive forms of PrPSc
Not tested for use in 
routine diagnostics 
or screening
28 29
4. Real-time quaking-
induced conversion 
(RT-QuIC)
Uses incubation and shaking to 
recapitulate and accelerate prion 
replication in vitro using recombinant 
prion protein (PrP) substrate
Ultra-sensitive for 
detecting low levels of 
sCJD PrPSc
Less able to detect 
vCJD PrPSc
32–34
5. Protein misfolded 
cyclic amplification 
(PMCA)
Uses incubation and sonication to 
recapitulate and accelerate prion 
replication in vitro using brain cellular 
prion protein PrPC substrate
Ultra-sensitive for 
detecting low levels of 
vCJD PrPSc
Less sensitive for 
sCJD PrPSc in our 
hands
30 31
CJD, Creutzfeldt-Jakob disease; PrP, prion protein; PrPSc, abnormal misfolded form of the PrP; sCJD, sporadic CJD; vCJD, Variant CJD.
Figure 2 Algorithm for assessing the results of biochemical 
analyses.
4. Single-round protein misfolding cyclic amplification 
(PMCA) for ultra-sensitive vCJD PrPSc detection.30 31
5. Real-time quaking-induced conversion (RT-QuIC) for 
ultra-sensitive sCJD PrPSc detection.32–34
Sensitivity of the PrP biochemical analysis methods
WB is a well-established diagnostic method used in prion 
disease research and surveillance but has limited sensi-
tivity. This technique is also limited to the detection of the 
protease-resistant form of the misfolded PrP. It may, there-
fore, be less able to detect new or atypical prion disease 
subtypes if a significant component of PrPSc is protease 
sensitive.23 The other four biochemical analysis methods 
(NaPTA, CDI, PMCA and RT-QuIC) used have higher 
sensitivities for detecting PrPSc, and RT-QuIC detection 
of prion seeding activity in cerebrospinal fluid is used in 
the UK to assist the clinical diagnosis of CJD patients.35 
However, the effectiveness of the four tests other than 
western blotting as methods for brain tissue sample 
screening is yet to be fully established. Therefore, when 
using this panel of biochemical analysis methods, careful 
consideration is given to the process used to assign posi-
tive results and to assess anomalous findings. Accordingly, 
we have developed an algorithm for each test that is used 
to facilitate classification of cases as ‘negative’ or ‘nega-
tive—anomalous’ or ‘positive’ as shown in figure 2.
Genotyping
PRNP codon 129 genotyping is performed using a sample 
of frontal cortex tissue for all cases used in this study, 
except for 65+ years study patients, where the codon 129 
genotype may already be known from a previous analysis 
of blood. The methionine (M)/valine (V) polymorphism 
at PRNP codon 129 affects prion disease clinicopatholog-
ical phenotype and susceptibility to prion disease at the 
population level.36 PRNP codon 129 genotyping is essen-
tial for classifying the different forms of prion disease. 
The process of genotyping involves extracting DNA from 
the frozen brain tissue samples (20–30 mg). Thereafter, 
PRNP codon 129 genotype analysis is performed by PCR 
and restriction fragment length polymorphism analysis.37
data management
All staff at NCJDRSU have a duty to maintain patient 
confidentiality, and procedures and relevant training are 
in place for data safeguarding. The University of Edin-
burgh has records management and information secu-
rity policies, procedures and guidance on the handling 
of confidential information. In addition, NCJDRSU has 
comprehensive information governance procedures to 
ensure data security and protection.
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All samples received from EBB (fixed and frozen) 
are de-identified by EBB staff, in line with EBB ethical 
approval prior to sharing with NCJDRSU. Samples are 
accompanied by a limited set of data only: The study 
requests the gender of the patients, their year of birth, 
age at death and post-mortem information, such as brain 
weight, pH and the time between death and post-mortem. 
All the results are documented and recorded in the study 
database at NCJDRSU. Paper records are filed securely 
at NCJDRSU in locked filing cabinets when not in use. 
Electronic records are processed in a password-protected 
controlled secured network with access restricted to 
named users on a need-to-know basis. At no point in time 
is personal information disclosed to anybody other than 
the named users; linkage of records for study analyses, 
and for follow-up, is restricted to authorised personnel by 
use of a unique study number.
Action for positive cases
The outcome of investigations is shared between the 
NCJDRSU and EBB study teams as part of the investi-
gation record. If there is evidence of vCJD, sCJD or 
other prion pathology, then further investigations are 
undertaken according to standard NCJDRSU surveil-
lance procedures.38 A final diagnostic report would 
be submitted to the senior clinician, then sent to the 
donor’s general practitioner for communication to the 
family.
Quality assurance
For quality assurance, and to test the sensitivity and spec-
ificity of the protocol, a blinded analysis is conducted 
in conjunction with the analysis of samples from EBB. 
Under the direction of the principal investigator, and 
in strict accordance with NCJDRSU category 3* labora-
tory health and safety policies, the blinded approach is 
undertaken as follows. A panel of human prion disease 
cases is used as positive controls. This panel includes 
vCJD cases, a range of sCJD subtypes and rarer forms, 
such as variably protease-sensitive prionopathy, to test 
the ability of the protocol to detect a range of prion 
disease subtypes, characterised by varying levels and 
isotypes of PrPSc.
The positive samples are anonymised and packaged in 
an identical manner to the ordinary study test samples, 
by the EBB and the NCJDRSU laboratory managers. 
True data for the positive cases are not attached to the 
samples because it could lead to the identification of the 
sample prior to testing. Instead, the positive samples are 
assigned dummy data, which is linked to their true iden-
tifiers using a coded key only known to the EBB and the 
NCJDRSU laboratory managers who are responsible for 
the blinding process. Researchers conducting the anal-
yses will not know which samples are positive or negative 
until the end of the planned analysis when the identities 
will be revealed. All results will be recorded in the study 
database.
disposal of samples
All residual tissue samples are retained until the end of 
the study, after which NCJDRSU will handle the disposal 
of any remaining samples in accordance with the EBB 
procedures. Samples from cases that are suspected to be 
CJD or any other prionopathy are retained routinely in 
the Brain and Tissue Bank at NCJDRSU. Any residual 
tissue or material linked to the positive samples (ie, frozen 
tissue samples, homogenates, microscope slides and 
DNA) are destroyed or returned to storage at NCJDRSU.
Statistical analysis
Any case with pathological evidence of prion disease 
which, prior to this study, was not considered to have prion 
disease is referred to as a ‘missed’ case of prion disease. 
Descriptive statistics, including frequency tables, cross-tab-
ulations and graphics, will be used to describe the demo-
graphics of the study population, including the date of 
death, age, sex and provenance of the donation. Clinical 
and pathological characteristics of the missed cases with 
attention to presenting features and in life (alternative) 
diagnoses will also be described. In addition, description 
of case classification (molecular subtype) and referral 
characteristics will be included. Univariate and multivari-
able analyses adjusting for potential confounders, such as 
age and sex, will be used to compare characteristics of 
missed cases with previously confirmed cases referred to 
NCJDRSU.
Ethics and approvals
Brain tissue donations are made voluntarily by the relatives 
of those involved, with consent for use in research. EBB 
has ethical approval to provide tissue samples to research 
projects (REC reference 16/ES/0084), including those 
for pilot studies. Findings of this study will be dissem-
inated in meetings, conferences and as peer-reviewed 
publications.
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